Brit J Cancer:放疗前中性粒细胞与淋巴细胞比率对口咽癌患者的预后意义

2020-10-15 MedSci原创 MedSci原创

RT前NLR是口咽癌患者的独立预后因素,与HPV状况无关。NLR较低的患者具有更好的OS,疾病得到了更好的控制。

近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,该研究旨在评估中性粒细胞与淋巴细胞比率(NLR)在口咽癌患者中的预后价值。

该研究纳入了2002年至2013年完成口咽癌放疗(RT)并在RT前进行了血液计数的患者。NLR计算为中性粒细胞/淋巴细胞总数。研究人员使用Kaplan-Meier方法估算了生存率,并使用线性和Cox回归方法进行单变量和多变量分析。研究人员对NLR进行了后验分析,并根据发现的中位数将其二等分。

研究人员分析了484例患者。RT前NLR的中位数为3。NLR<3的患者总生存率(OS)高于NLR≥3的患者(5年OS为85 vs. 74%,p<0.0001)。根据HPV状况分层时,OS差异仍然很显著(HPV阳性p=0.011;HPV阴性p=0.003)。NLR<3的患者无任何复发(FFR)、局部区域控制(LRC)和无远处复发(FDR)。RT前NLR升高对OS具有负面效应(HR=1.64,p=0.001),在多变量分析中,FFR(HR=1.6,p=0.006)和LRC(HR=1.8,p=0.005)仍然很显著。

由此可见,RT前NLR是口咽癌患者的独立预后因素,与HPV状况无关。NLR较低的患者具有更好的OS,疾病得到了更好的控制。

原始出处:

Sweet Ping Ng,al et.Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy.British Journal of Cancer.2020.https://www.nature.com/articles/s41416-020-01106-x

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1296747, encodeId=77211296e473d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302340, encodeId=b48d130234070, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350652, encodeId=e487135065230, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546259, encodeId=8e3a1546259b6, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1296747, encodeId=77211296e473d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302340, encodeId=b48d130234070, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350652, encodeId=e487135065230, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546259, encodeId=8e3a1546259b6, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1296747, encodeId=77211296e473d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302340, encodeId=b48d130234070, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350652, encodeId=e487135065230, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546259, encodeId=8e3a1546259b6, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1296747, encodeId=77211296e473d, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302340, encodeId=b48d130234070, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350652, encodeId=e487135065230, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546259, encodeId=8e3a1546259b6, content=<a href='/topic/show?id=a6fa100185d7' target=_blank style='color:#2F92EE;'>#预后意义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100185, encryptionId=a6fa100185d7, topicName=预后意义)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba9d13903217, createdName=haouestc, createdTime=Fri Oct 16 23:17:07 CST 2020, time=2020-10-16, status=1, ipAttribution=)]

相关资讯

Lancet oncol:术前放疗对腹膜后肉瘤患者预后的影响

与四肢肉瘤不同,放疗对腹膜后肉瘤的疗效尚未明确。本研究旨在评估术前放疗联合手术与单纯手术对腹部肉瘤患者无复发生存预后的影响。

BMJ:保乳手术术中放疗治疗早期乳腺癌

对于可以接受保乳治疗的早期乳腺癌患者,术中接受单次放疗的治疗效果与术后体外放射治疗相当,并且非乳腺癌死亡率较低

Lancet:根治性手术后立即进行辅助放疗对前列腺癌患者无事件生存率的影响

对于局部或局部晚期前列腺癌患者,在根治性手术后接受辅助放疗不能显著提高患者无事件生存率

CSCO于振涛:食管癌新辅助治疗研究与展望

相比国际领域,国内食管癌研究稍显落后,相信我们未来食管癌新辅助治疗研究会有大的突破,能够打开我们精准的食管癌治疗的大门。

Cancer Immunol Res :揭示胰腺癌放疗抵抗新机制!杨旭光等研究人员发现代谢分子乳酸促进抑制性免疫微环境导致胰腺癌放疗抵抗!

胰腺癌是恶性程度最高的肿瘤之一,被称为“癌中之王”。放射治疗在胰腺癌治疗中发挥重要作用,但是胰腺癌放疗抵抗常常导致放疗失败和肿瘤复发,胰腺癌产生放疗抵抗的机制尚不清楚。

Prostate Cancer P D:镭-223治疗去势抵抗性前列腺癌研究

镭-223和化疗治疗转移去势抵抗性前列腺癌(mCRPC)的最优排序在指南中尚不存在。最近,有研究人员在学术临床环境中评估了镭-223治疗mCRPC患者的治疗模式和总生存(OS)情况。